Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 0.600nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 0.760nMAssay Description:In vivo assays for 15-PGDH expression or 15-PGDH activity, e.g., ligands, agonists, antagonists, and their homologs and mimetics. The term modulator ...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 0.970nMAssay Description:Assays were done by measuring the transfer of tritium from 15(S)-[15-3H] PGE2 to glutamate (at 1 μM PGE2 substrate), or by direct fluorescence m...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 0.970nMAssay Description:It is not clearly defined.More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 0.970nMAssay Description:In vivo assays for 15-PGDH expression or 15-PGDH activity, e.g., ligands, agonists, antagonists, and their homologs and mimetics. The term modulator ...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 0.970nMAssay Description:Each compound for inhibiting enzymatic activity of recombinant 15-PGDH in an in vitro assay. More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 0.970nMAssay Description:This Example provides data on a group of structural analogues of SW033291. Data provided includes level of induction of a 15-PGDH-luciferase fusion g...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant human C-terminal 6xHis-tagged 15-PGDH expressed in Escherichia coli using PGE2 as substrate after 15 mins in presence of NA...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant human C-terminal 6xHis-tagged 15-PGDH expressed in Escherichia coli using PGE2 as substrate after 15 mins in presence of NA...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.14nMAssay Description:Assays were done by measuring the transfer of tritium from 15(S)-[15-3H] PGE2 to glutamate (at 1 μM PGE2 substrate), or by direct fluorescence m...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.14nMAssay Description:Each compound for inhibiting enzymatic activity of recombinant 15-PGDH in an in vitro assay. More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.14nMAssay Description:It is not clearly defined.More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.23nMAssay Description:In vivo assays for 15-PGDH expression or 15-PGDH activity, e.g., ligands, agonists, antagonists, and their homologs and mimetics. The term modulator ...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.23nMAssay Description:This Example provides data on a group of structural analogues of SW033291. Data provided includes level of induction of a 15-PGDH-luciferase fusion g...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.30nMAssay Description:It is not clearly defined.More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.30nMAssay Description:Each compound for inhibiting enzymatic activity of recombinant 15-PGDH in an in vitro assay. More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.30nMAssay Description:Each compound for inhibiting enzymatic activity of recombinant 15-PGDH in an in vitro assay. More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.30nMAssay Description:Assays were done by measuring the transfer of tritium from 15(S)-[15-3H] PGE2 to glutamate (at 1 μM PGE2 substrate), or by direct fluorescence m...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.30nMAssay Description:Inhibition of recombinant human C-terminal 6xHis-tagged 15-PGDH expressed in Escherichia coli using PGE2 as substrate after 15 mins in presence of NA...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.34nMAssay Description:Each compound for inhibiting enzymatic activity of recombinant 15-PGDH in an in vitro assay. More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.34nMAssay Description:It is not clearly defined.More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.34nMAssay Description:Assays were done by measuring the transfer of tritium from 15(S)-[15-3H] PGE2 to glutamate (at 1 μM PGE2 substrate), or by direct fluorescence m...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.37nMAssay Description:It is not clearly defined.More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.37nMAssay Description:Assays were done by measuring the transfer of tritium from 15(S)-[15-3H] PGE2 to glutamate (at 1 μM PGE2 substrate), or by direct fluorescence m...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.37nMAssay Description:It is not clearly defined.More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.37nMAssay Description:This Example provides data on a group of structural analogues of SW033291. Data provided includes level of induction of a 15-PGDH-luciferase fusion g...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.37nMAssay Description:Each compound for inhibiting enzymatic activity of recombinant 15-PGDH in an in vitro assay. More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.37nMAssay Description:Assays were done by measuring the transfer of tritium from 15(S)-[15-3H] PGE2 to glutamate (at 1 μM PGE2 substrate), or by direct fluorescence m...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.37nMAssay Description:In vivo assays for 15-PGDH expression or 15-PGDH activity, e.g., ligands, agonists, antagonists, and their homologs and mimetics. The term modulator ...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.37nMAssay Description:Each compound for inhibiting enzymatic activity of recombinant 15-PGDH in an in vitro assay. More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.40nMAssay Description:Inhibition of recombinant human C-terminal 6xHis-tagged 15-PGDH expressed in Escherichia coli using PGE2 as substrate after 15 mins in presence of NA...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.40nMAssay Description:Inhibition of recombinant human C-terminal 6xHis-tagged 15-PGDH expressed in Escherichia coli using PGE2 as substrate after 15 mins in presence of NA...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.41nMAssay Description:Assays were done by measuring the transfer of tritium from 15(S)-[15-3H] PGE2 to glutamate (at 1 μM PGE2 substrate), or by direct fluorescence m...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.41nMAssay Description:This Example provides data on a group of structural analogues of SW033291. Data provided includes level of induction of a 15-PGDH-luciferase fusion g...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.41nMAssay Description:Each compound for inhibiting enzymatic activity of recombinant 15-PGDH in an in vitro assay. More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.41nMAssay Description:In vivo assays for 15-PGDH expression or 15-PGDH activity, e.g., ligands, agonists, antagonists, and their homologs and mimetics. The term modulator ...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.41nMAssay Description:It is not clearly defined.More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.43nMAssay Description:It is not clearly defined.More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.43nMAssay Description:Assays were done by measuring the transfer of tritium from 15(S)-[15-3H] PGE2 to glutamate (at 1 μM PGE2 substrate), or by direct fluorescence m...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.43nMAssay Description:Each compound for inhibiting enzymatic activity of recombinant 15-PGDH in an in vitro assay. More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:Inhibition of recombinant human C-terminal 6xHis-tagged 15-PGDH expressed in Escherichia coli using PGE2 as substrate after 15 mins in presence of NA...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.60nMAssay Description:This Example provides data on two groups (Table 1 and Table 2) of structural analogues of identified 15-PGDH inhibitors. Data provided is the IC50 of...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.60nMAssay Description:Inhibition of 15-PGDH (unknown origin) using NAD as substrate measured for 3.5 minsMore data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.70nMAssay Description:This Example provides data on two groups (Table 1 and Table 2) of structural analogues of identified 15-PGDH inhibitors. Data provided is the IC50 of...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.70nMAssay Description:This Example provides data on two groups (Table 1 and Table 2) of structural analogues of identified 15-PGDH inhibitors. Data provided is the IC50 of...More data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.70nMAssay Description:Inhibition of 15-PGDH (unknown origin) using NAD as substrate measured for 3.5 minsMore data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.70nMAssay Description:Inhibition of 15-PGDH (unknown origin) using NAD as substrate measured for 3.5 minsMore data for this Ligand-Target Pair
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics
US Patent
Myoforte Therapeutics
US Patent
Affinity DataIC50: 1.80nMAssay Description:Inhibition of recombinant human C-terminal 6xHis-tagged 15-PGDH expressed in Escherichia coli using PGE2 as substrate after 15 mins in presence of NA...More data for this Ligand-Target Pair